Where innovation meets validation.
We identify the United States as the undeniable epicenter of the upcoming MedTech supercycle. We back companies that meet FDA approval—the undisputed gold standard for global market access.
Your FDA clearance is an entry ticket.
For U.S. MedTech companies, the Middle East is arguably the most strategic, lucrative, and frictionless first step for global expansion. Here is why:
Fast-Track FDA Reciprocity
GCC regulators primarily act as verifiers, not original auditors. Your FDA clearance (or CE Mark) dramatically expedites the process, cutting time-to-market down to months rather than years.
The "Hub & Spoke" Advantage
Securing a license in a major hub like the UAE or Saudi Arabia creates a domino effect, enabling rapid, low-cost expansion into the rest of the Gulf.
A Premium Addressable Market
Gain immediate access to 61 million residents—roughly 20% of the U.S. population. The region is characterized by high disposable income and a robust, insurance-based healthcare system.
Zero Friction
English is the absolute standard for business, medicine, and regulatory affairs across the region. No translation layers, no lost momentum.
Strict parameters for extraordinary growth.
Our primary mandate is investing directly into U.S. Parent Companies. We look for category-defining businesses backed by execution-oriented leadership and top-tier VCs.
1. Stage & Market Defensibility
Growth Stage: Market-proven product and a scalable model with a minimum of $5M Trailing Twelve Months (TTM) revenue or contracted ARR.
Pre-Commercial Stage: R&D complete and technology validated. We take on regulatory risk only, not technical risk.
The Moat: Operating in a large, expanding market capable of supporting a $1B+ equity valuation. Must demonstrate a Strong Unique Value Proposition (UVP) with robust protection against broad copying.
Business Model: Preference for high-margin, recurring revenue models (SaaS, subscriptions, marketplace commissions).
2. Regulatory Visibility & Reimbursement
For pre-commercial stage companies, we require explicit regulatory validation:
510(k) Pathway: Completed FDA Pre-Submission (Q-Sub) meeting with a confirmed predicate strategy AND Design Freeze status.
PMA Pathway: FDA Approval for Feasibility Studies (IDE) OR Breakthrough Device Designation granted.
Digital Health: Validated "Enforcement Discretion" status backed by a tier-1 legal opinion.
Reimbursement Strategy: Verified ability to utilize existing CPT/HCPCS codes or a clearly defined roadmap for securing new coverage (e.g., NTAP status, Category III codes).
3. The GCC Accelerator (Optional Strategic Pathway)
While our primary focus is the U.S. market, we offer a dedicated, fully-funded pathway for companies ready to monetize the Middle East. To unlock our regional market-entry infrastructure through a dedicated GCC Subsidiary, companies must demonstrate:
- Financial Trajectory: A credible plan to achieve $5M+ revenue in the GCC within 3 years, with a clear path to EBITDA profitability within 24-36 months.
- Skin in the Game: The U.S. Parent must independently secure or contribute at least 20% of the required regional financing.
- IP & Structuring: Exclusive, long-term license or full IP transfer to the GCC entity, coupled with a defined share-swap option for liquidity.
Domain expertise. Principal execution.
Connect directly with the partners and directors leading our MedTech and Longevity allocations.
